MX2012004851A - Purification of staphylococcus aureus type 5 and type 8 capsular saccharides. - Google Patents

Purification of staphylococcus aureus type 5 and type 8 capsular saccharides.

Info

Publication number
MX2012004851A
MX2012004851A MX2012004851A MX2012004851A MX2012004851A MX 2012004851 A MX2012004851 A MX 2012004851A MX 2012004851 A MX2012004851 A MX 2012004851A MX 2012004851 A MX2012004851 A MX 2012004851A MX 2012004851 A MX2012004851 A MX 2012004851A
Authority
MX
Mexico
Prior art keywords
type
cells
purification
staphylococcus aureus
capsular saccharides
Prior art date
Application number
MX2012004851A
Other languages
Spanish (es)
Inventor
Paolo Costantino
Francesco Berti
Maria Rosaria Romano
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43513776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012004851(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2012004851A publication Critical patent/MX2012004851A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Abstract

The invention provides a method for releasing capsular polysaccharide from S.aureus type 5 or type 8 cells, comprising the step of treating the cells with acid. The invention further provides a process for purifying capsular polysaccharide from S.aureus type 5 or type 8 cells comprising this method. Other processing steps may be included in the process, such as enzymatic treatment, e.g. to remove nucleic acid, protein and/or peptidoglycan contaminants; diafiltration, e.g. to remove low molecular weight contaminants; anion exchange chromatography, e.g. to remove residual protein; and concentration.
MX2012004851A 2009-10-30 2010-11-01 Purification of staphylococcus aureus type 5 and type 8 capsular saccharides. MX2012004851A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25690509P 2009-10-30 2009-10-30
PCT/IB2010/054934 WO2011051917A1 (en) 2009-10-30 2010-11-01 Purification of staphylococcus aureus type 5 and type 8 capsular saccharides

Publications (1)

Publication Number Publication Date
MX2012004851A true MX2012004851A (en) 2012-05-22

Family

ID=43513776

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015017594A MX345967B (en) 2009-10-30 2010-11-01 Purification of staphylococcus aureus type 5 and type 8 capsular saccharides.
MX2012004851A MX2012004851A (en) 2009-10-30 2010-11-01 Purification of staphylococcus aureus type 5 and type 8 capsular saccharides.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015017594A MX345967B (en) 2009-10-30 2010-11-01 Purification of staphylococcus aureus type 5 and type 8 capsular saccharides.

Country Status (22)

Country Link
US (5) US9060965B2 (en)
EP (2) EP2493498B1 (en)
JP (4) JP5914344B2 (en)
CN (2) CN102971009A (en)
AU (1) AU2010310919B2 (en)
BR (2) BR122019005883A8 (en)
CA (1) CA2779578A1 (en)
CL (1) CL2012001145A1 (en)
CY (1) CY1118905T1 (en)
DK (1) DK2493498T3 (en)
ES (1) ES2626416T3 (en)
HR (1) HRP20170674T1 (en)
HU (1) HUE034251T2 (en)
LT (1) LT2493498T (en)
MX (2) MX345967B (en)
PL (1) PL2493498T3 (en)
PT (1) PT2493498T (en)
RS (1) RS56000B1 (en)
RU (1) RU2579900C2 (en)
SG (1) SG10201407096RA (en)
SI (1) SI2493498T1 (en)
WO (1) WO2011051917A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180221466A9 (en) * 2006-06-12 2018-08-09 Glaxosmithkline Biologicals S.A. Use of alpha-toxin for treating and preventing staphylococcus infections
MY169837A (en) 2009-06-22 2019-05-16 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
BRPI1011753B8 (en) 2009-06-22 2021-05-25 Wyeth Llc immunogenic conjugates of capsular polysaccharide from staphylococcus aureus serotypes 5 and 8, their use and compositions comprising them
ES2812523T3 (en) 2009-09-30 2021-03-17 Glaxosmithkline Biologicals Sa Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
CN102971009A (en) 2009-10-30 2013-03-13 诺华有限公司 Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
US9109036B2 (en) 2011-02-08 2015-08-18 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
CN102660602B (en) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 Method for rapidly purifying bacteria capsular polysaccharide
SI2890394T1 (en) * 2012-08-31 2019-06-28 Glaxosmithkline Biologicals Sa Stabilised proteins for immunising against staphylococcus aureus
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
CA2919412A1 (en) * 2013-07-26 2015-01-29 University Of Saskatchewan Methods for producing salmonella o-antigen capsules, compositions and uses thereof
US20170281744A1 (en) 2014-12-10 2017-10-05 Glaxosmithkline Biologicals Sa Method of treatment
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7239509B6 (en) 2019-02-22 2023-03-28 ファイザー・インク Method for purifying bacterial polysaccharides
US20210070890A1 (en) 2019-09-06 2021-03-11 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
US10828360B1 (en) * 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation
WO2021165847A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
CA3199094A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
CN112986457B (en) * 2021-02-25 2022-07-12 中国食品药品检定研究院 Method for detecting polysaccharide by HPSEC-MALS method and correlating polysaccharide with Sepharose CL-4B method
CN113234770A (en) * 2021-06-15 2021-08-10 广州知易生物科技有限公司 Preparation method of bacteroides fragilis capsular polysaccharide A
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
CN114957509B (en) * 2022-08-01 2022-10-21 深圳柏垠生物科技有限公司 Scalable purification method of kola acid

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2166963A (en) * 1936-11-19 1939-07-25 Sharp & Dohme Inc Antigenic polysaccharide complex
DK105490C (en) * 1961-05-15 1966-10-03 Parke Davis & Co Process for the preparation of a staphylococcal antigen product in the form of immunogenic polysaccharide compounds.
US3269913A (en) * 1962-05-11 1966-08-30 Parke Davis & Co Staphylococcal-immunizing products and methods for their production
GB995338A (en) * 1963-09-20 1965-06-16 Parke Davis & Co Polysaccharides and methods for their production
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4663160A (en) * 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US5055455A (en) * 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
KR920703114A (en) 1989-07-14 1992-12-17 원본미기재 Cytokines and Hormone Carriers for Conjugate Vaccines
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE
EP0471177B1 (en) 1990-08-13 1995-10-04 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
FR2682388B1 (en) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc PROCESS FOR THE PREPARATION OF AN OLIGOSIDE BY DEPOLYMERIZATION OF A POLYOSIDE DERIVED FROM A PATHOGENIC AGENT, OLIGOSIDE THUS OBTAINED AND ITS USE IN PARTICULAR AS A VACCINE AGENT.
JP4087896B2 (en) * 1991-11-22 2008-05-21 ナビ・バイオフアーマシユテイカルズ Staphylococcus epidermidis type I and type II surface antigens
IT1262896B (en) 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur Proteinase k resistant surface protein of neisseria meningitidis
US6743430B1 (en) * 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
JP4233113B2 (en) 1995-06-07 2009-03-04 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム Vaccine comprising polysaccharide antigen-carrier protein conjugate and free carrier protein
US5770208A (en) 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US6294177B1 (en) * 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
WO1998042718A1 (en) 1997-03-26 1998-10-01 The Brigham And Women's Hospital, Inc. Method for generating saccharide fragments
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
CN1263854C (en) 1997-11-06 2006-07-12 启龙股份公司 Neisserial antigens
CA2307846A1 (en) 1997-11-21 1999-06-03 Genset S.A. Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
WO1999028475A2 (en) 1997-11-28 1999-06-10 Genset Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
WO1999036544A2 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP1645631B1 (en) 1998-05-01 2007-10-24 Novartis Vaccines and Diagnostics, Inc. Neisseria antigens and compositions
US7252828B2 (en) * 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
JP2004511201A (en) 1998-10-09 2004-04-15 カイロン　コーポレイション Neisseria genome sequences and methods of using them
CA2350775A1 (en) 1998-11-12 2000-05-18 The Regents Of The University Of California Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
HUP0200664A2 (en) 1999-03-19 2002-06-29 Smithkline Beecham Biolog Streptococcus vaccine
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
JP2002541808A (en) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Recombinant toxin A protein carrier for polysaccharide conjugate vaccine
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US6689567B1 (en) * 1999-05-28 2004-02-10 University Of Guelph Method for assaying the function of FlaA1 and WbpM
MXPA02006962A (en) 2000-01-17 2002-12-13 Chiron Spa Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins.
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
US6537577B1 (en) * 2001-06-04 2003-03-25 Bio Medical Development Corporation Method of prophylaxis for bovine mastitis
GB2379996B (en) * 2001-06-05 2004-05-19 Tayside Flow Technologies Ltd Flow means
ATE429484T1 (en) * 2001-06-11 2009-05-15 Applied Nanosystems Bv METHOD FOR BINDING ACMA-TYPE PROTEIN ANCHOR FUSIONS TO MICROORGANISMS CELL WALL MATERIALS
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US20040161741A1 (en) 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
AU2003257003A1 (en) 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
US20060121058A1 (en) * 2002-08-08 2006-06-08 Children's Medical Center Corporation Anti-pneumococcal preparations
AU2003260102A1 (en) 2002-08-26 2004-03-11 Chiron Corporation Conserved and specific streptococcal genomes
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
CA2498847C (en) 2002-09-13 2014-10-28 Chiron Corporation Group b streptococcus vaccine
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
PT1565478T (en) 2002-11-12 2017-11-14 The Brigham And Women`S Hospital Inc Polysaccharide vaccine for staphylococcal infections
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
KR20060035581A (en) 2003-03-07 2006-04-26 와이어쓰 홀딩스 코포레이션 Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US8084235B2 (en) 2003-03-13 2011-12-27 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
WO2005000346A1 (en) * 2003-06-23 2005-01-06 Baxter International Inc. Carrier proteins for vaccines
BRPI0412799A (en) 2003-07-24 2006-09-26 Merck & Co Inc immunogen, composition, nucleic acid, recombinant cell, methods for preparing a polypeptide, for inducing a protective immune response in a patient and for inducing an anamnesic response in a patient, and optimized yeast nucleic acid sequence
US20060188515A1 (en) 2003-07-24 2006-08-24 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphylococcus aureus
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
KR101161033B1 (en) * 2003-09-11 2012-06-28 드 슈타트 데르 네덜란덴, 베르테겐부어디그트 두어 드 미니스터 반 폭스겐트존하이트 벨지인 엔 스포츠 Process for producing a capsular polysaccharide for use in conjugate vaccines
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1725575B1 (en) 2004-02-18 2012-11-28 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against staphylococcus aureus
US20070172498A1 (en) 2004-02-27 2007-07-26 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphyloococcus aureus
US20050250821A1 (en) * 2004-04-16 2005-11-10 Vincent Sewalt Quaternary ammonium compounds in the treatment of water and as antimicrobial wash
US7842479B2 (en) * 2004-05-21 2010-11-30 The Board Of Regents Of The University Of Nebraska Methods for altering acetic acid production and enhancing cell death in bacteria
CN1956727A (en) 2004-05-25 2007-05-02 默克公司 Polypeptides for inducing a protective immune response against staphylococcus aureus
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
US20070264278A1 (en) 2004-09-17 2007-11-15 Anderson Annaliesa S Polypeptides for Inducing a Protective Immune Response Against Staphylococcus Aureus
US20080085289A1 (en) 2004-09-22 2008-04-10 Cindy Castado Immunogenic Composition
US20060134141A1 (en) 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
CA2593265A1 (en) 2005-01-21 2006-07-27 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
GB0502096D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
US20060228368A1 (en) 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
FR2884830A1 (en) 2005-04-25 2006-10-27 Sanofi Pasteur Sa Producing an overexpressive strain of Staphylococcus aureus for producing a polysaccharide capsular, comprises culturing the strain on a culture medium and optionally recovering the produced strain from the medium
EP3009146B1 (en) * 2005-06-27 2021-10-20 Pfizer Ireland Pharmaceuticals Immunogenic composition
EP1937304A2 (en) * 2005-08-24 2008-07-02 Novartis Vaccines and Diagnostics S.r.l. Zwitterionization of capsular saccharides
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
JP5286089B2 (en) * 2006-01-13 2013-09-11 バクスター・インターナショナル・インコーポレイテッド Method for purifying polysaccharides
AR060187A1 (en) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa IMMUNOGENIC COMPOSITION
KR101541383B1 (en) 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. immunogenic composition
FR2899110A1 (en) * 2006-03-31 2007-10-05 Sanofi Pasteur Sa Immunogenic composition, useful for immunizing against Staphylococcus aureus infection, comprises capsular polysaccharide of type 8 and 5 of Staphylococcus aureus strain overproducing type 8 and/or type 5, respectively
JP2009539979A (en) 2006-06-12 2009-11-19 ナビ バイオファーマシューティカルズ Use of alpha toxins to treat and prevent staphylococcal infections
GB0612854D0 (en) * 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
CA2667788A1 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
EP2094317B1 (en) * 2006-11-08 2010-09-15 B-K Medical ApS Method for multi-step sterilization
DE102006062398A1 (en) 2006-12-20 2008-06-26 Edi (Experimentelle & Diagnostische Immunologie) Gmbh Methods for detecting and / or characterizing cellular activity patterns, use of toll-like receptor ligands (TLR ligands) and a kit
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
CA2687681A1 (en) 2007-05-31 2009-03-05 Merck & Co., Inc. Antigen-binding proteins targeting s. aureus orf0657n
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
WO2009029831A1 (en) 2007-08-31 2009-03-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
WO2009106073A2 (en) 2008-02-28 2009-09-03 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
EP2344523B1 (en) * 2008-09-17 2016-02-10 GlaxoSmithKline Biologicals SA Combination gas vaccines and therapeutics
WO2010042481A1 (en) * 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
US8668911B2 (en) * 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
BRPI1011753B8 (en) * 2009-06-22 2021-05-25 Wyeth Llc immunogenic conjugates of capsular polysaccharide from staphylococcus aureus serotypes 5 and 8, their use and compositions comprising them
MY169837A (en) 2009-06-22 2019-05-16 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
GB0913681D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
ES2812523T3 (en) 2009-09-30 2021-03-17 Glaxosmithkline Biologicals Sa Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
CN102971009A (en) 2009-10-30 2013-03-13 诺华有限公司 Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
CN102695718A (en) * 2009-12-28 2012-09-26 龟甲万株式会社 Method for extracting staphylococcus aureus antigen, reagent for extracting staphylococcus aureus antigen, and method for testing staphylococcus aureus
US9173954B2 (en) * 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
US8821894B2 (en) * 2010-07-02 2014-09-02 The University Of Chicago Compositions and methods related to protein A (SpA) variants
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
JP2016540764A (en) 2013-12-04 2016-12-28 グリコヴァキシン アーゲー Prevention of Staphylococcus aureus infection by glycoprotein vaccine synthesized in Escherichia coli
US9775872B2 (en) 2014-08-20 2017-10-03 Professional Compounding Centers Of America Topical pharmaceutical bases for preventing viral diseases
KR20200018787A (en) * 2017-05-22 2020-02-20 더 칠드런스 메디칼 센터 코포레이션 Combination vaccine against mycobacterium tuberculosis

Also Published As

Publication number Publication date
EP2493498A1 (en) 2012-09-05
RS56000B1 (en) 2017-09-29
JP5914344B2 (en) 2016-05-11
MX345967B (en) 2017-02-28
US9441004B2 (en) 2016-09-13
US20220089627A1 (en) 2022-03-24
RU2579900C2 (en) 2016-04-10
ES2626416T3 (en) 2017-07-25
US11208424B2 (en) 2021-12-28
US20160376301A1 (en) 2016-12-29
HUE034251T2 (en) 2018-02-28
BR112012010223A2 (en) 2016-12-06
JP2013509397A (en) 2013-03-14
CL2012001145A1 (en) 2012-09-14
RU2012122237A (en) 2013-12-10
SG10201407096RA (en) 2014-12-30
CA2779578A1 (en) 2011-05-05
HRP20170674T1 (en) 2017-07-14
PT2493498T (en) 2017-05-24
AU2010310919A1 (en) 2012-05-24
BR122019005883A8 (en) 2022-10-04
EP2493498B1 (en) 2017-03-22
US20150315225A1 (en) 2015-11-05
AU2010310919B2 (en) 2015-05-07
JP2017206564A (en) 2017-11-24
SI2493498T1 (en) 2017-07-31
JP2019104940A (en) 2019-06-27
EP3199177A1 (en) 2017-08-02
BR122019005883A2 (en) 2019-09-03
CY1118905T1 (en) 2018-01-10
PL2493498T3 (en) 2017-08-31
DK2493498T3 (en) 2017-05-08
US9060965B2 (en) 2015-06-23
CN109134677A (en) 2019-01-04
US20190169216A1 (en) 2019-06-06
JP2016047852A (en) 2016-04-07
CN102971009A (en) 2013-03-13
US20120282295A1 (en) 2012-11-08
WO2011051917A1 (en) 2011-05-05
LT2493498T (en) 2017-05-25

Similar Documents

Publication Publication Date Title
MX2012004851A (en) Purification of staphylococcus aureus type 5 and type 8 capsular saccharides.
WO2010090860A3 (en) Methods and compositions for treating bacterial infection
NZ620988A (en) Method for purifying recombinant adamts13 and other proteins and compositions thereof
EA201290152A1 (en) ANTISMINAL INHIBITORS OF HEPATITIS B VIRUS (HBV)
UA93384C2 (en) Process for manufacture of sterilized powder pancreatin
WO2010063996A3 (en) Antibacterial compounds
MX2011010249A (en) Method for combating harmful fungi.
WO2007141274A3 (en) Human binding molecules having killing activity against staphylococci and uses thereof
MX2009004986A (en) Methods of treating hemolytic anemia.
MY159600A (en) Electrochemical device for biocide treatment in agricultural applications
WO2008070672A3 (en) Compositions and methods to treat cancer with cupredoxins and cpg rich dna
WO2010151784A3 (en) Antimicrobial compounds
BRPI0607850A2 (en) method for treating copper-containing materials
SG184375A1 (en) Non-destructive method for algae contaminated water treatment and algae harvest or removal
WO2008085962A3 (en) Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
WO2012061502A3 (en) Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
MX359930B (en) Methods of treatment.
BR112015021883A2 (en) method for treating microorganisms during propagation, conditioning and fermentation using hop acid extract and organic acid
WO2008070347A3 (en) Betulin-peptide conjugates
WO2005089426A3 (en) Method of treating sepsis
WO2006116380A3 (en) Plasma or serum fraction for the treatment or prevention of bacterial infections
WO2007103767A3 (en) Role of microrna in plant salt tolerance
BRPI0816724A2 (en) PROCESS FOR INCREASING PH VALUE OF ACID WATER BODIES
WO2010114919A3 (en) Metnase and intnase inhibitors and their use in treating cancer
WO2010039189A3 (en) Methods for sequencing degraded or modified nucleic acids